ERBB2 and breast carcinoma: Collectively, our results demonstrate that fibroblast-derived factors modulate response to lapatinib in a subset of HER2 + breast cancer cell lines and that proteomic profiling of the fibroblast-protected state uncovers previously known targets of HER2 therapy resistance.